List of Excipients in Branded Drug NEURONTIN

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Parke-Davis Div of Pfizer Inc	NEURONTIN	gabapentin	0071-0803	FD&C BLUE NO. 2
Parke-Davis Div of Pfizer Inc	NEURONTIN	gabapentin	0071-0803	GELATIN
Parke-Davis Div of Pfizer Inc	NEURONTIN	gabapentin	0071-0803	LACTOSE
Parke-Davis Div of Pfizer Inc	NEURONTIN	gabapentin	0071-0803	STARCH, CORN
Parke-Davis Div of Pfizer Inc	NEURONTIN	gabapentin	0071-0803	TALC
Parke-Davis Div of Pfizer Inc	NEURONTIN	gabapentin	0071-0803	TITANIUM DIOXIDE

Neurontin Excipient Strategy and Commercial Opportunities for Gabapentin

Last updated: October 6, 2026

Neurontin is Pfizer’s brand of gabapentin, an off-patent small-molecule drug available in capsules, tablets, and oral solution. The commercial opportunity is no longer primary-molecule exclusivity. It is formulation execution: lower-cost excipient systems, improved swallowability, pediatric and geriatric presentations, allergen and colorant removal, and differentiated oral delivery. Gabapentin’s saturable intestinal transport makes excipient selection and dissolution control important because formulation changes can affect exposure and bioequivalence.

What is Neurontin and which formulations does it contain?

Neurontin contains gabapentin, an anticonvulsant approved in the United States for postherpetic neuralgia and as adjunctive therapy for partial seizures in patients three years and older. Pfizer markets or historically marketed three immediate-release dosage forms:

Dosage form	Typical strengths	Main commercial use
Capsules	100 mg, 300 mg, 400 mg	Adult titration and maintenance
Tablets	600 mg, 800 mg	Higher-dose adult treatment
Oral solution	250 mg/5 mL	Pediatric, geriatric, and dysphagia patients

The FDA-approved Neurontin label identifies the active ingredient as gabapentin and describes the product as an immediate-release oral medicine. Gabapentin has no meaningful metabolism and is eliminated primarily through the kidneys, which makes renal dosing more important than hepatic formulation effects. [1]

Neurontin should be distinguished from:

• Gralise, an extended-release gabapentin product for postherpetic neuralgia.
• Horizant, gabapentin enacarbil, a prodrug with a separate absorption and regulatory profile.
• Generic immediate-release gabapentin products, which compete directly with Neurontin.

These products should not be treated as interchangeable formulation platforms.

What excipients are used in Neurontin capsules, tablets, and oral solution?

The Neurontin dosage forms use conventional excipient systems. Exact composition varies by dosage form and strength.

Neurontin capsule excipients

Neurontin capsules use a hard gelatin shell and may contain:

• Lactose
• Corn starch
• Talc
• Titanium dioxide
• Pharmaceutical colorants, including FD&C Yellow No. 6 in certain strengths
• Gelatin

The capsule platform is low-cost and easy to manufacture. Its commercial disadvantages include lactose exposure, gelatin use, colorant sensitivity, capsule swallowing difficulty, and higher packaging and handling costs compared with a simple tablet.

Neurontin tablet excipients

The tablet formulation uses excipients associated with direct compression or conventional granulation, including:

• Corn starch
• Copovidone
• Magnesium stearate
• Poloxamer 407
• Film-coating components

The tablet platform supports higher strengths and lower unit counts. The 600 mg and 800 mg presentations are commercially useful because gabapentin treatment frequently requires dose escalation. The primary formulation challenge is tablet size. High-strength gabapentin tablets can be difficult for patients with dysphagia, neurological impairment, or age-related swallowing limitations.

Neurontin oral solution excipients

The oral solution contains a vehicle system based on:

• Glycerin
• Xylitol
• Purified water
• Flavoring
• Methylparaben
• Propylparaben

This system provides a sugar-free liquid presentation and supports dose titration. Xylitol can cause gastrointestinal effects at high intake levels, while parabens may limit positioning in some pediatric, clean-label, or preservative-sensitive markets. The liquid also has higher packaging, shipping, microbial-control, and stability requirements than tablets or capsules. [1]

Which excipient attributes matter most for gabapentin?

Gabapentin presents a specific formulation issue: absorption is mediated by a saturable L-amino acid transport system in the intestine. Bioavailability declines as the dose increases. Reported absolute bioavailability is approximately 60% at 900 mg per day and approximately 27% at 4,800 mg per day, although exposure depends on dose, schedule, and product design. [1,2]

The most important excipient variables are:

Excipient variable	Commercial and regulatory relevance
Disintegration rate	Controls release of gabapentin from tablets and capsules
Dissolution profile	Supports immediate-release performance and ANDA similarity
Lubricant level	Excess magnesium stearate can slow wetting and dissolution
Binder concentration	Affects hardness, friability, and disintegration
Granulation method	Influences content uniformity and scale-up
Moisture level	Affects powder flow, stability, and capsule or tablet performance
Sweetener system	Determines pediatric acceptability and gastrointestinal tolerance
Preservative system	Controls microbial risk in oral solution
Flavor system	Affects adherence and pediatric acceptance
Colorants and shell materials	Determines allergen, dietary, and patient-preference positioning

The key development objective is not simply rapid dissolution. It is reproducible, immediate-release dissolution across the full commercial dose range without creating a clinically meaningful change in exposure.

What excipient strategy is best for a generic Neurontin product?

The strongest generic strategy is a low-risk formulation that remains close to the established immediate-release profile while removing avoidable supply-chain and patient-use disadvantages.

Strategy 1: Use a simple, robust tablet platform

A manufacturer can use microcrystalline cellulose, pregelatinized starch, crospovidone or croscarmellose sodium, colloidal silicon dioxide, and a controlled level of magnesium stearate. This approach can reduce reliance on:

• Lactose
• Talc
• Gelatin
• Colorants
• Proprietary coating systems
• Complex granulation steps

A direct-compression or dry-granulation process may reduce manufacturing cost, but gabapentin’s high-dose tablet load can create flow, segregation, and tablet-size problems. Wet granulation may improve compactability but adds process time and moisture exposure.

Strategy 2: Develop a lactose-free and gelatin-free product

Lactose-free tablets and hypromellose capsules address patients with lactose intolerance, dietary restrictions, or preference for non-animal-derived materials. A gelatin-free capsule can use hypromellose or pullulan, although the cost is usually higher than a standard gelatin shell.

This positioning is commercially useful but does not create regulatory exclusivity. It is a product attribute that can support pharmacy contracting, institutional supply, and direct-to-consumer differentiation.

Strategy 3: Remove artificial colors

A color-free product can reduce sensitivity concerns and simplify global regulatory submissions. Color removal also avoids strength-specific color coding, which may be replaced with embossing, shape, or packaging controls.

The tradeoff is medication-identification risk. If multiple strengths have similar appearance, packaging and tablet imprinting must carry more of the differentiation burden.

Strategy 4: Optimize the oral solution for pediatric use

A differentiated liquid product could use:

• A low-sugar or sugar-free vehicle
• A xylitol-free alternative where gastrointestinal tolerance is a concern
• A more acceptable flavor system
• A lower-volume concentrated presentation
• A preservative system with broad microbial protection
• A child-resistant, unit-dose, or oral-syringe-compatible package

Any concentration change creates dosing and labeling issues. A 250 mg/5 mL product has established market familiarity, while a more concentrated formulation could reduce administration volume but increase medication-error risk.

Strategy 5: Develop a dispersible or orally disintegrating presentation

A dispersible tablet or orally disintegrating tablet could address dysphagia and improve administration in selected populations. Gabapentin’s relatively high daily dose limits the practicality of a small, rapidly disintegrating unit. Taste masking is also necessary because gabapentin can produce an unpleasant mouthfeel.

A multiparticulate granule, sprinkle capsule, or sachet may be more commercially practical than an ODT for patients who cannot swallow conventional tablets. These products require careful control of dose uniformity, moisture, packaging, and administration instructions.

What FDA regulatory pathway applies to generic Neurontin?

Immediate-release generic gabapentin products generally use the abbreviated new drug application pathway under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant must demonstrate pharmaceutical equivalence and bioequivalence to the relevant reference listed drug.

For excipients, the practical requirements are:

1. Use inactive ingredients with an established regulatory history or support their safety.
2. Demonstrate that the formulation remains pharmaceutically equivalent.
3. Meet dissolution requirements across relevant strengths.
4. Address inactive-ingredient differences through the ANDA review.
5. Establish stability, content uniformity, microbial quality, and manufacturing consistency.
6. Provide adequate labeling for excipient-related warnings where applicable.

A change in excipient quantity can be material even when the excipient itself is familiar. The risk is highest when the change affects dissolution, gastrointestinal transit, osmolarity, taste, or liquid-product preservation.

For oral solutions, applicants must control concentration, pH, viscosity, preservative effectiveness, microbial limits, and dose-delivery accuracy. For tablets and capsules, dissolution and in vitro release are central to the development package.

What patents protect Neurontin, and when did exclusivity end?

Gabapentin is no longer protected by meaningful U.S. compound-patent exclusivity. The original Neurontin patent estate expired years ago, and immediate-release generic gabapentin products have been approved for many years.

The commercial exclusivity position is:

Exclusivity category	Neurontin status
Compound patent	Expired
Immediate-release formulation patents	No material blocking exclusivity remains
FDA new chemical entity exclusivity	Expired
Pediatric exclusivity	Expired
Orange Book blocking position	Generic competition established
Immediate-release generic entry	Active and broad
Biosimilar pathway	Not applicable

Historical patent disputes involving Neurontin centered on patent enforcement, generic entry, and alleged conduct surrounding the drug’s commercial positioning. Those disputes do not restore current market exclusivity for immediate-release gabapentin. [3,4]

The patent analysis is different for Gralise and Horizant. Extended-release delivery and gabapentin enacarbil are separate products with separate patents and regulatory requirements. A manufacturer cannot rely on Neurontin’s expired immediate-release estate to launch either product.

What is the Orange Book status of Neurontin?

The FDA Orange Book identifies approved drug products, reference listed drugs, patents, and exclusivity information. Neurontin’s immediate-release dosage forms have been exposed to generic competition, and gabapentin is widely available from multiple manufacturers. The relevant business question is not whether a generic can enter, but whether a new formulation can obtain approval and gain distribution against low-cost established suppliers. [5]

A reformulated gabapentin product may require a different regulatory pathway if it is not pharmaceutically equivalent to the reference listed drug. A new dosage form, new concentration, modified-release design, or new route of administration could require a 505(b)(2) application rather than a conventional ANDA.

Are there Paragraph IV challenges to Neurontin?

Paragraph IV litigation was commercially relevant during the historical generic-entry period for Neurontin and related gabapentin products. It is not a current barrier to ordinary immediate-release generic entry because the principal Neurontin exclusivity period has ended and generic products are established in the market.

For a new formulation, Paragraph IV analysis depends on the specific Orange Book-listed patents for the reference product and any separate patents covering the proposed formulation. A manufacturer pursuing a differentiated product must distinguish:

• Expired Neurontin patents
• Active patents covering a separate extended-release product
• Method-of-use patents
• Formulation patents
• Manufacturing or solid-state patents
• Patents listed against a different gabapentin product

Patent clearance for immediate-release gabapentin is materially less complex than for extended-release gabapentin or gabapentin prodrugs.

Are there biosimilar risks for Neurontin?

No. Neurontin is a chemically synthesized small molecule, not a biologic. Biosimilar approval rules do not apply.

The competitive threats are:

• ANDA-approved generic gabapentin
• Authorized generic supply
• Hospital and pharmacy contracting
• Formulation-based substitutes
• Extended-release gabapentin products
• Alternative neuropathic-pain medicines, including pregabalin and duloxetine

Pregabalin is the most direct therapeutic comparison, but its patent, controlled-substance, and commercial history differ from gabapentin. Duloxetine competes in neuropathic pain but uses a different mechanism and formulation platform.

How does the Neurontin patent estate compare with competing gabapentin products?

Product	Active ingredient	Release profile	Main protection issue	Generic or follow-on risk
Neurontin	Gabapentin	Immediate release	Historical compound and use patents expired	High
Gralise	Gabapentin	Extended release	Formulation and release-control patents	Higher than Neurontin
Horizant	Gabapentin enacarbil	Prodrug, extended release	Product-specific patents and exclusivity	Product-specific
Generic gabapentin	Gabapentin	Immediate release	Low differentiation	High
Pregabalin products	Pregabalin	Immediate or controlled formulations	Separate patent estate	Product-specific

Neurontin has the weakest patent position but the broadest manufacturing familiarity. Gralise and Horizant have stronger formulation barriers but smaller addressable markets and more complex development requirements.

What commercial opportunities remain for gabapentin excipients?

The opportunity is in margin and market access rather than patent monopoly.

Hospital and institutional supply

Hospitals may value:

• Consistent supply
• Latex-free and color-free formulations
• Unit-dose packaging
• Barcode-ready presentations
• Low tablet-breakage rates
• Simplified formulary management

A manufacturer with reliable excipient sourcing can compete even in a low-price market where the active ingredient is commoditized.

Pediatric and geriatric products

Oral liquids, smaller tablets, dispersible products, and oral-syringe-compatible packages address patients who cannot swallow standard dosage forms. Taste, dosing accuracy, and caregiver convenience are more important in these segments than minor tablet-cost differences.

Clean-label and dietary positioning

Lactose-free, gelatin-free, dye-free, and gluten-free positioning can support retail and specialty-pharmacy differentiation. These claims require accurate supplier qualification and finished-product testing. They do not independently provide patent protection.

Global supply-chain resilience

Excipient selection can reduce dependence on a single supplier or region. A dual-source strategy for binders, disintegrants, lubricants, film coatings, flavors, and preservatives can reduce shortage risk. The formulation must be designed so that approved supplier changes do not alter dissolution or stability.

Lifecycle management

A company could pursue a 505(b)(2) product based on:

• A lower-volume oral liquid
• A dispersible or sprinkle formulation
• A modified-release product
• A new delivery device
• A patient-specific concentration
• A combination product

The commercial case must justify development costs against low-cost generic gabapentin. A new formulation with no clear adherence, safety, dosing, or administration advantage is unlikely to support premium pricing.

What generic launch risks exist for a new Neurontin formulation?

The principal risks are commercial and technical:

1. Gabapentin API is widely available and inexpensive.
2. Existing generic products establish low price benchmarks.
3. High-dose tablets restrict the ability to create compact dosage forms.
4. Saturable transport complicates extrapolation across strengths and formulations.
5. Taste and mouthfeel can limit liquid and ODT adoption.
6. Oral solutions require more demanding microbial and stability controls.
7. Excipients that improve manufacturability can slow dissolution.
8. A 505(b)(2) product may face active patents covering a different release technology.
9. Pharmacy substitution can undermine premium positioning.
10. Payers may treat the product as therapeutically interchangeable with generic gabapentin.

How strong is the current Neurontin patent estate?

The immediate-release Neurontin patent estate is commercially weak because compound and primary product exclusivity have expired. The remaining defensible value lies in execution, trademarks, product-specific formulation claims, and any newly developed delivery technology.

A prospective formulation patent should focus on measurable technical features such as:

• Defined dissolution windows
• Specific particle-size distributions
• Controlled release of high-dose gabapentin
• Taste-masking matrices
• Stable preservative systems
• Multiparticulate delivery
• Reduced-volume liquid formulations
• Manufacturing processes that improve content uniformity

Broad claims covering gabapentin with routine excipients are vulnerable to written-description, enablement, obviousness, and anticipation challenges. Claims tied to demonstrated performance are more defensible.

What licensing deals affect Neurontin?

Neurontin was historically associated with Warner-Lambert and Pfizer following Pfizer’s acquisition of Warner-Lambert. The important commercial licensing question today concerns access to formulation technology, manufacturing know-how, delivery systems, or regional distribution rather than a license to the basic gabapentin molecule.

For a new entrant, the most relevant deal structures are:

• Contract manufacturing agreements
• Excipient and coating-technology licenses
• Regional distribution rights
• Authorized-generic arrangements
• Co-development of pediatric or geriatric products
• Device and packaging licenses

No license to the expired Neurontin compound patent is needed for ordinary immediate-release generic gabapentin manufacture.

Key Takeaways

• Neurontin is immediate-release gabapentin in capsules, tablets, and oral solution.
• Its core patent and exclusivity position has expired.
• The active ingredient is commoditized, so commercial value must come from formulation, supply, packaging, or patient-use advantages.
• Gabapentin’s saturable intestinal absorption makes dissolution and formulation consistency important.
• The strongest near-term opportunities are lactose-free, gelatin-free, dye-free, pediatric, geriatric, dispersible, and lower-volume liquid products.
• Biosimilar risk does not apply because gabapentin is a small molecule.
• Gralise and Horizant require separate patent and regulatory analyses.
• A generic immediate-release product generally follows the ANDA pathway; materially different delivery systems may require 505(b)(2) development.
• Formulation patents should claim demonstrated technical performance rather than routine excipient combinations.
• The main launch risk is low pricing and automatic substitution, not molecule-level patent litigation.

FAQs

Can gabapentin tablets be reformulated without new clinical trials?

Often, an ANDA can support an equivalent immediate-release formulation through pharmaceutical equivalence, dissolution, and bioequivalence data. A materially different dosage form, concentration, release profile, or route may require a 505(b)(2) application and additional clinical support.

Is lactose-free Neurontin commercially differentiated?

Lactose-free gabapentin can differentiate a product for selected patients and institutions, but lactose removal does not create exclusivity. The commercial benefit depends on labeling, procurement, payer treatment, and distribution.

What is the best excipient for improving gabapentin tablet disintegration?

There is no universal best excipient. Crospovidone, croscarmellose sodium, and sodium starch glycolate can improve disintegration, but the optimal choice depends on compression force, lubricant level, particle size, moisture, and dissolution targets.

Can a gabapentin oral solution use a different preservative system?

Yes, subject to FDA inactive-ingredient requirements, preservative-effectiveness testing, stability, microbial limits, and product-specific regulatory review. Any new preservative system must maintain safety and quality over the labeled shelf life.

Does Gralise have the same patent position as Neurontin?

No. Gralise is an extended-release gabapentin product with a separate formulation and patent analysis. The expiration of immediate-release Neurontin patents does not automatically eliminate Gralise-related barriers.

References

1. Pfizer Inc. (2023). Neurontin (gabapentin) prescribing information. U.S. Food and Drug Administration.

2. Stewart, B. H., Kugler, A. R., Thomson, A. H., & Bockbrader, H. N. (1993). A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma. Pharmaceutical Research, 10(2), 276-281.

3. U.S. Court of Appeals for the Federal Circuit. (2009). Tafas v. Doll and related federal patent litigation records concerning Warner-Lambert gabapentin patents.

4. U.S. District Court for the District of Massachusetts. (2010). In re Neurontin Marketing, Sales Practices, and Products Liability Litigation. MDL No. 1629.

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.